HRT Financial’s TScan Therapeutics TCRX Stock Holding History

HRT Financial’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$161K	Buy	+164,601	New	+$175K	﹤0.01%	3469
2026 Q1	–	Sell	-26,581	Closed	-$26K	–	4706
2025 Q4	$26K	Buy	+26,581	New	+$38.5K	﹤0.01%	2960
2025 Q3	–	Sell	-55,369	Closed	-$80K	–	3656
2025 Q2	$80K	Buy	+55,369	New	+$80K	﹤0.01%	2242
2024 Q2	–	Sell	-34,789	Closed	-$276K	–	3084
2024 Q1	$276K	Buy	+34,789	New	+$219K	﹤0.01%	1608
2022 Q1	–	Sell	-20,829	Closed	-$93K	–	3843
2021 Q4	$93K	Buy	+20,829	New	+$150K	﹤0.01%	2777

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

HRT Financial's TCRX Position: Q2 2026 in Review

HRT Financial opened a new position in TScan Therapeutics (TCRX) in Q2 2026: 164,601 shares worth $161K. The stake represents ﹤0.01% of the portfolio and ranks #3469 among its holdings. This is a return to the name: HRT Financial previously reported a position in TCRX as recently as Q4 2025.

HRT Financial first reported a position in TCRX in Q4 2021 and has held it in 5 quarters since. The position peaked at $276K in Q1 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

HRT Financial held 164,601 shares of TScan Therapeutics worth $161K as of Q2 2026.
TScan Therapeutics was a new HRT Financial position in Q2 2026.
TScan Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q2 2026, its #3469 holding.
HRT Financial first reported a position in TScan Therapeutics in Q4 2021 and has held it in 5 quarters since.
HRT Financial's TScan Therapeutics position peaked at $276K in Q1 2024.
60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.